** Shares of biotech firm Protara Therapeutics TARA.O rise 50% to $5.32 premarket
** Co says its experimental cell therapy to treat a type of bladder cancer helped remove all signs of cancer in 72% of patients at six months of treatment in an open-label mid-stage study
** The therapy, TARA-002, showed a favorable safety and tolerability profile and no patients discontinued due to side-effects - TARA
** TARA-002 is being developed to treat high-risk non-muscle invasive bladder cancer (NMIBC)
** Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing ~80% of bladder cancer diagnoses -TARA
** Up to last close, stock up ~89% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。